A novel drug, the immune cell-directing antibody amivantamab (beneath improvement by Janssen), has proven promise for the therapy of sufferers with non–small cell lung most cancers (NSCLC) with exon 20 insertion mutations within the epidermal development issue receptor gene (EGFR) after illness development with chemotherapy.

Outcomes from the section 1 CHRYSALIS research present that efficacy of the drug is “strong,” with antitumor exercise “noticed in all affected person subgroups,” commented lead researcher Joshua Ok. Sabari, MD, assistant professor, Division of Drugs, New York College Faculty of Drugs, New York, Metropolis.

He added that the tolerability profile of the drug is according to expectations.

The research was introduced on the World Convention on Lung Most cancers (WCLC) 2020 on January 29.

Amivantamab is currently awaiting approval in the US and Europe to be used within the therapy of sufferers with NSCLC and EGFR exon 20 insertion mutations whose illness has progressed on or after platinum-based chemotherapy. No therapies are at the moment accepted for cancers with this mutation, the corporate famous. The brand new drug has been granted breakthrough remedy designation.

“There’s a vital want for brand new therapy choices for sufferers with NSCLC and EGFR exon 20 insertion mutations, whose illness usually doesn’t reply properly to chemotherapy and the tyrosine kinase inhibitors used to deal with different EGFR mutations,” Sabari commented within the press launch.

“That is excellent news for our sufferers,” commented Karen Reckamp, MD, director, Division of Medical Oncology, Cedars-Sinai Most cancers Institute, Los Angeles, California, who was not concerned within the research.

She defined that the share of NSCLC circumstances in which there’s an EGFR mutation varies from 15% to twenty% amongst combined Western populations and is 70% amongst Asian populations. The exon 20 insertion accounts for about 10% of all EGFR mutations.

“With a worldwide incidence of two million circumstances, this can be a substantial group of sufferers who might profit from novel therapies,” she advised Medscape Medical Information.

The administration of those sufferers has been a “problem”; nonetheless, “not like activating mutations, the conformation doesn’t enable for optimum binding of normal EGFR tyrosine kinase inhibitors [TKIs], leading to restricted efficacy,” she mentioned.

Reckamp identified that the inhabitants included within the present research was “heterogeneous with respect to variety of prior therapies, and the follow-up is lower than a 12 months, so these outcomes might want to mature.”

However, “if the numbers stay within the vary of those section 1 information, this remedy would profit most sufferers with EGFR exon 20–mutant NSCLC,” she mentioned; the exercise of the drug is “promising,” and the toxicity is “as we might anticipate.”

Particulars of CHRYSALIS Outcomes

Amivantamab is a completely human bispecific antibody that targets each activating and resistance EGFR mutations and MET mutations and amplifications. It has been proven to be lively as monotherapy for sufferers with a spread of EGFR mutations.

The present evaluation from the CHRYSALIS trial was based mostly on 81 sufferers with NSCLC with EGFR exon 20 insertions who had skilled illness development with platinum-based chemotherapy. The median age of the sufferers was 62 years, and 41% had been males.

Nearly all of sufferers had been Asian (49%) or White (37%). Simply over half (53%) had been nonsmokers. The median variety of prior traces of remedy was two; 46% had undergone immunotherapy along with chemotherapy, and 25% had acquired a TKI.

All sufferers acquired amivantamab. Sufferers who weighed <80 kg acquired a dose 1050 mg, and those that weighed ≥80 kg acquired a dose of 1400 mg.

After a median follow-up of 9.7 months, for sufferers who acquired amivantamab, the general response fee was 40% at a median length of response of 11.1 months. The scientific profit fee, outlined as an entire or partial response or steady illness on at the least two illness assessments, was 74%.

The drug seemed to be equally efficient throughout subgroups based mostly on age, intercourse, race, prior traces of remedy, and historical past of smoking.

On the premise of the present information, the crew calculates that the median progression-free survival with amivantamab was 8.3 months and that the median total survival was 22.8 months.

Commenting on these outcomes on Twitter, Stephen V. Liu, MD, director of thoracic oncology at Georgetown College, Washington, DC, mentioned the dosing schedule for the drug is “suboptimal for comfort” however that it’s “efficient and properly tolerated.”

Consequently, he appears ahead to “having this as an choice.”


A security evaluation based mostly on this research and on a previous dose-escalation research confirmed that the most typical treatment-emergent hostile occasions had been rash (86%), infusion-related reactions (66%) and paronychia (45%). Stomatitis (21%) and pruritus (17%) had been additionally reported. Sabari famous that diarrhea occurred in 12% of sufferers; for 3.5% of sufferers, the diarrhea was of grade 3.

Adversarial occasions of grade ≥3 had been reported in 35% of sufferers; 16% of these occasions had been thought of therapy associated. Rash (4%) and infusion-related reactions (3%) had been had been essentially the most frequent.

No treatment-related deaths had been reported. Remedy-related hostile occasions led to dose reductions in 13% of sufferers and to discontinuation in 4%.

The producer notes that scientific improvement of amivantamab in untreated superior EGFR-mutated NSCLC is continuous within the section 3 MARIPOSA and PAPILLON mixture trials.

The research was sponsored by Janssen Analysis & Growth, LLC. Sabari has relationships with AstraZeneca, Genentech, Janssen, Navire, Pfizer, Regeneron, Sanofi Genzyme, Takeda. Reckamp has relationships with Janssen.

World Convention on Lung Most cancers (WCLC) 2020: Summary OA04.04. Offered January 29, 2021.

For extra from Medscape Oncology, be part of us on Twitter and Facebook.